.Attribute Medicine, Released online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA permission after an unfavorable trial, which highlights the various complexities and challenges of medication advancement in this particular setup.